Los Angeles Capital Management LLC I Mab Transaction History

Los Angeles Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$8.27 - $18.43 $256,957 - $572,638	-31,071 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$12.54 - $46.93 $76,481 - $286,226	-6,099 Reduced 16.41%	31,071 $505,000
Q4 2021 Feb 03, 2022	SELL	$45.28 - $74.5 $156,034 - $256,727	-3,446 Reduced 8.48%	37,170 $1.76 Million
Q3 2021 Nov 08, 2021	BUY	$57.18 - $84.43 $1.46 Million - $2.16 Million	25,556 Added 169.69%	40,616 $2.94 Million
Q2 2021 Aug 05, 2021	BUY	$47.86 - $83.95 $720,771 - $1.26 Million	15,060 New	15,060 $1.26 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.